250 related articles for article (PubMed ID: 9189215)
1. Quantification of HIV-1 viral load in lymphoid and blood cells: assessment during four-drug combination therapy.
Tamalet C; Lafeuillade A; Fantini J; Poggi C; Yahi N
AIDS; 1997 Jun; 11(7):895-901. PubMed ID: 9189215
[TBL] [Abstract][Full Text] [Related]
2. Antiretroviral effect of zidovudine-didanosine combination on blood and lymph nodes.
Lafeuillade A; Tamalet C; Poggi C; Pellegrino P; Tourres C; Izopet J
AIDS; 1997 Jan; 11(1):67-72. PubMed ID: 9110077
[TBL] [Abstract][Full Text] [Related]
3. A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study.
García F; Romeu J; Grau I; Sambeat MA; Dalmau D; Knobel H; Gomez-Sirvent JL; Arrizabalaga J; Cruceta A; Clotet BG; Podzamczer D; Pumarola T; Gallart T; O'Brien WA; Miró JM; Gatell JM
AIDS; 1999 Dec; 13(17):2377-88. PubMed ID: 10597779
[TBL] [Abstract][Full Text] [Related]
4. Pilot study of a combination of highly active antiretroviral therapy and cytokines to induce HIV-1 remission.
Lafeuillade A; Poggi C; Chadapaud S; Hittinger G; Chouraqui M; Pisapia M; Delbeke E
J Acquir Immune Defic Syndr; 2001 Jan; 26(1):44-55. PubMed ID: 11176268
[TBL] [Abstract][Full Text] [Related]
5. Pilot study of zidovudine-lamivudine combination therapy in vertically HIV-infected antiretroviral-naive children.
Horneff G; Adams O; Wahn V
AIDS; 1998 Mar; 12(5):489-94. PubMed ID: 9543447
[TBL] [Abstract][Full Text] [Related]
6. Effect of antiretroviral combination therapy (zidovudine/didanosine or zidovudine/lamivudine) on quantitative plasma human immunodeficiency virus-ribonucleic acid in children and adolescents infected with human immunodeficiency virus.
Sölder B; Wintergerst U; Notheis G; Eberle J; Gürtler L; Belohradsky BH
J Pediatr; 1997 Feb; 130(2):293-9. PubMed ID: 9042135
[TBL] [Abstract][Full Text] [Related]
7. Efficacy, safety, and adherence with a twice-daily combination lamivudine/zidovudine tablet formulation, plus a protease inhibitor, in HIV infection.
Eron JJ; Yetzer ES; Ruane PJ; Becker S; Sawyer GA; Fisher RL; Tolson JM; Shaefer MS
AIDS; 2000 Apr; 14(6):671-81. PubMed ID: 10807190
[TBL] [Abstract][Full Text] [Related]
8. Decrease of HIV-1 RNA levels in lymphoid tissue and peripheral blood during treatment with ritonavir, lamivudine and zidovudine. Ritonavir/3TC/ZDV Study Group.
Notermans DW; Jurriaans S; de Wolf F; Foudraine NA; de Jong JJ; Cavert W; Schuwirth CM; Kauffmann RH; Meenhorst PL; McDade H; Goodwin C; Leonard JM; Goudsmit J; Danner SA
AIDS; 1998 Jan; 12(2):167-73. PubMed ID: 9468365
[TBL] [Abstract][Full Text] [Related]
9. AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients.
AIDS; 2000 Mar; 14(4):367-74. PubMed ID: 10770538
[TBL] [Abstract][Full Text] [Related]
10. Quantitative molecular monitoring of HIV-1 RNA during antiretroviral therapy.
Lafeuillade A; Poggi C; Pellegrino P; Profizi N
Infection; 1996; 24(6):412-8. PubMed ID: 9007587
[TBL] [Abstract][Full Text] [Related]
11. Human immunodeficiency virus type 1 dynamics in different lymphoid tissue compartments.
Lafeuillade A; Poggi C; Tamalet C; Profizi N
J Infect Dis; 1997 Sep; 176(3):804-6. PubMed ID: 9291339
[TBL] [Abstract][Full Text] [Related]
12. Human immunodeficiency virus proviral DNA from peripheral blood and lymph nodes demonstrates concordant resistance mutations to zidovudine (codon 215) and didanosine (codon 74). Division of AIDS Treatment Research Initiative 003 Study Group.
Mayers D; Bethel J; Wainberg MA; Weislow O; Schnittman S
J Infect Dis; 1998 Jun; 177(6):1730-3. PubMed ID: 9607859
[TBL] [Abstract][Full Text] [Related]
13. The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients.
Schapiro JM; Winters MA; Stewart F; Efron B; Norris J; Kozal MJ; Merigan TC
Ann Intern Med; 1996 Jun; 124(12):1039-50. PubMed ID: 8633817
[TBL] [Abstract][Full Text] [Related]
14. A dose-ranging study to evaluate the safety and efficacy of abacavir alone or in combination with zidovudine and lamivudine in antiretroviral treatment-naive subjects.
Staszewski S; Katlama C; Harrer T; Massip P; Yeni P; Cutrell A; Tortell SM; Harrigan RP; Steel H; Lanier RE; Pearce G
AIDS; 1998 Nov; 12(16):F197-202. PubMed ID: 9833847
[TBL] [Abstract][Full Text] [Related]
15. Long-term evaluation of triple nucleoside therapy administered from primary HIV-1 infection.
Poggi C; Profizi N; Djediouane A; Chollet L; Hittinger G; Lafeuillade A
AIDS; 1999 Jul; 13(10):1213-20. PubMed ID: 10416525
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.
Katlama C; Ingrand D; Loveday C; Clumeck N; Mallolas J; Staszewski S; Johnson M; Hill AM; Pearce G; McDade H
JAMA; 1996 Jul; 276(2):118-25. PubMed ID: 8656503
[TBL] [Abstract][Full Text] [Related]
17. Correspondence between the effect of zidovudine plus lamivudine on plasma HIV level/CD4 lymphocyte count and the incidence of clinical disease in infected individuals. North American Lamivudine HIV Working Group.
Phillips AN; Eron J; Bartlett J; Kuritzkes DR; Johnson VA; Gilbert C; Johnson J; Keller A; Hill AM
AIDS; 1997 Feb; 11(2):169-75. PubMed ID: 9030363
[TBL] [Abstract][Full Text] [Related]
18. Cell-associated HIV-1-DNA quantitation after highly active antiretroviral therapy-treated primary infection in patients with persistently undetectable plasma HIV-1 RNA.
Garrigue I; Pellegrin I; Hoen B; Dumon B; Harzic M; Schrive MH; Séréni D; Fleury H
AIDS; 2000 Dec; 14(18):2851-5. PubMed ID: 11153666
[TBL] [Abstract][Full Text] [Related]
19. Predicting the duration of antiviral treatment needed to suppress plasma HIV-1 RNA.
Rizzardi GP; De Boer RJ; Hoover S; Tambussi G; Chapuis A; Halkic N; Bart PA; Miller V; Staszewski S; Notermans DW; Perrin L; Fox CH; Lange JM; Lazzarin A; Pantaleo G
J Clin Invest; 2000 Mar; 105(6):777-82. PubMed ID: 10727446
[TBL] [Abstract][Full Text] [Related]
20. HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial. The National Virology Groups. Delta Virology Working Group and Coordinating Committee.
Brun-Vézinet F; Boucher C; Loveday C; Descamps D; Fauveau V; Izopet J; Jeffries D; Kaye S; Krzyanowski C; Nunn A; Schuurman R; Seigneurin JM; Tamalet C; Tedder R; Weber J; Weverling GJ
Lancet; 1997 Oct; 350(9083):983-90. PubMed ID: 9329513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
